ASH 2018 | A personalized prediction model to risk stratify patients with MDS

Aziz Nazha

Myelodysplastic syndrome (MDS) patients have very heterogeneous outcomes in terms of overall survival. Here, Aziz Nazha, MD, of the Cleveland Clinic, Cleveland, OH, discusses a personalized prediction model that uses clinical-, molecular-, and transplant-related data predict the probability of survival for individual MDS patients, aiding HCPs and patients in their decision-making prior to transplant. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.